We announced the closing of our $140 million Series B financing. – Harbinger Health

Harbinger Health shared on LinkedIn:

“Today, we announced the closing of our $140 million Series B financing.

We’re grateful for the support of our investors, including Flagship Pioneering, Pictet Group, Partners Group Investment and Catalyst, M&G Investments’ purpose-led private assets strategy, among other global institutional investors.

With this funding, we will accelerate the advancement of our proprietary two-tier testing model for early-stage cancers, expand our team, and support the completion of our ongoing CORE-HH study, as well as initiate additional clinical studies in high-risk populations.

We’re thrilled to be taking another step toward our goal of making early-stage cancer screening accessible on a global scale.”

For details click here.
For the video click here.
Source: Harbinger Health/LinkedIn